1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  05/20 02:00:00 am EDT
3536.00 JPY   +0.31%
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
04/28Chugai Pharmaceutical Co., Ltd. - Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
AQ
04/27CHUGAI PHARMACEUTICAL : Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical Co., Ltd. - Notice of Board of Director's Resolution on Application for New Market Segment 'Prime Market'

12/20/2021 | 10:04am EDT

Name of listed company: Chugai Pharmaceutical Co., Ltd.

Code number: 4519 (1st Section of Tokyo Stock Exchange)

Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo

President & CEO: Osamu Okuda

Inquiries to: Toshiya Sasai

Head of Corporate Communications Dept.

Chugai Pharmaceutical Co., Ltd. (hereafter the 'Company') announces that the Company resolved at the meeting of its Board of Directors held today, to apply for listing on the 'Prime Market,' one of the new market segments of the Tokyo Stock Exchange (TSE).

On July 9, 2021, the Company received the notice of initial assessment by the TSE, confirming that it is in compliance with the continued listing criteria for the Prime Market in the new market segments.

The Company will follow the prescribed procedures related to the application for the selection of the new market segments in accordance with the schedule set by the TSE.

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

Investors

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group

Corporate Communications Dept.

Takayuki Sakurai

Tel: +81-3-3273-0554

E-mail: ir@chugai-pharm.co.jp

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD 0.31% 3536 Delayed Quote.-5.33%
ROCHE HOLDING AG 0.88% 319.7 Delayed Quote.-15.67%
All news about CHUGAI PHARMACEUTICAL CO., LTD
05/18Judgement On The First Drug Patent Linkage Lawsuit In China Is Issued
AQ
04/28Chugai Pharmaceutical Co., Ltd. - Notice of Completion of Disposal of Treasury Shares a..
AQ
04/27CHUGAI PHARMACEUTICAL : Notice of Completion of Disposal of Treasury Shares as Restricted ..
PU
04/26CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
04/26Chugai Pharmaceutical Co., Ltd. - Organizational and Personnel Changes
AQ
04/26Nikkei 225 Up 0.4% on Wall Street Cues, Softer Interest Rates, Oil Outlook
MT
04/26Chugai Pharmaceutical Logs 178% Surge in Q1 Net Income on Higher Sales
MT
04/25CHUGAI PHARMACEUTICAL : 1Q Results (Jan-Mar 2022)
PU
04/25Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces First Quarter Sales 20..
AQ
04/25CHUGAI PHARMACEUTICAL : Supplementary Materials for Consolidated Financial Results for the..
PU
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 187 B 9 282 M 9 282 M
Net income 2022 343 B 2 679 M 2 679 M
Net cash 2022 604 B 4 723 M 4 723 M
P/E ratio 2022 17,0x
Yield 2022 2,20%
Capitalization 5 815 B 45 478 M 45 478 M
EV / Sales 2022 4,39x
EV / Sales 2023 4,88x
Nbr of Employees 7 664
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 536,00 JPY
Average target price 4 677,69 JPY
Spread / Average Target 32,3%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-5.33%45 478
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707